Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term antibody. Found 22 abstracts

no pagination
Wissler HL, Ehlerding EB, Lyu Z, Zhao Y, Zhang S, Eshraghi A, Buuh ZY, McGuth JC, Guan Y, Engle JW, Bartlett SJ, Voelz VA, Cai W, Wang RE. Site-Specific Immuno-PET Tracer to Image PD-L1. Molecular pharmaceutics. 2019 May 06;16(5):2028-36.   PMCID: PMC6521698
D'Souza JW, Hensley H, Doss M, Beigarten C, Torgov M, Olafsen T, Yu JQ, Robinson MK. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers. J Nucl Med. 2017 Jan;58(1):175-80.   PMCID: PMC5209641
D'Souza JW, Robinson MK. Oligoclonal antibodies to target the ErbB family. Expert Opin Biol Ther. 2015 May 02;15(7):1015-21.   PMCID: 4480362
Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu YH, Schwartz JD, Thompson JA. A Phase 2, Single-Arm Study of Ramucirumab in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy. Cancer. 2014 Jun;120(11):1647-55.   PMCID: No NIH funding
Fang M, Siciliano NA, Hersperger AR, Roscoe F, Hu A, Ma XY, Shamsedeen AR, Eisenlohr LC, Sigal LJ. Perforin-dependent CD4(+) T-cell cytotoxicity contributes to control a murine poxvirus infection. Proceedings of the National Academy of Sciences of the United States of America. 2012 Jun;109(25):9983-8.   PMCID: PMC3382508
Weiss RF, Miller MG, Cronin JF, Hensley HH, Joshi ID, Smith MR. Parametric Model of Combination Therapy for Non-Hodgkin Lymphoma. Plos One. 2012 Dec;7(12):e51736.   PMCID: PMC 3522695
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets. 2009 Mar;13(3):339-62.   PMCID: PMC2670612
Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy - Protein engineering strategies to improve exposure in solid tumors. Cancer. 2007 Jan;109(2):170-9.
Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, Tolmachev V, Carlsson J. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 Jun;33(6):631-8.
Louzoun Y, Friedman R, Prak EL, Litwin S, Weigert M. Analysis of B cell receptor production and rearrangement Part 1. Light chain rearrangement. Seminars in immunology. 2002 Jun;14(3):169-90.
Lozano F, Simarro M, Calvo J, Vila JM, Padilla O, Bowen MA, Campbell KS. CD5 signal transduction: Positive or negative modulation of antigen receptor signaling. Critical reviews in immunology. 2000 Jan;20(4):347-58.
Hayakawa K, Asano M, Shinton SA, Gui M, Allman D, Stewart CL, Silver J, Hardy RR. Positive selection of natural autoreactive B cells. Science (New York, NY). 1999 Jul 02;285(5424):113-6.
Kraj P, Rao SP, Glas AM, Hardy RR, Milner EC, Silberstein LE. The human heavy chain Ig V region gene repertoire is biased at all stages of B cell ontogeny, including early pre-B cells. Journal of Immunology. 1997 Jun 15;158(12):5824-32.
Krop I, deFougerolles AR, Hardy RR, Allison M, Schlissel MS, Fearon DT. Self-renewal of B-1 lymphocytes is dependent on CD19. European Journal of Immunology. 1996 Jan;26(1):238-42.
LevyMintz P, Duan LX, Zhang HZ, Hu BC, Dornadula G, Zhu MH, Kulkosky J, BizubBender D, Skalka AM, Pomerantz RJ. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. Journal of Virology. 1996 Dec;70(12):8821-32.
Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD. Isolation of high-affinity monomeric human Anti-c-erbB-2 single chain Fv using affinity-driven selection. Journal of Molecular Biology. 1996 Jan 12;255(1):28-43.
Feitelson MA, Duan LX, Guo J, Sun B, Woo J, Steensma K, Horiike N, Blumberg BS. X-Region Deletion Variants of Hepatitis-B Virus in Surface Antigen-Negative Infections and Non-a, Non-B-Hepatitis. Journal of Infectious Diseases. 1995 Sep;172(3):713-22.
Soler AP, Knudsen KA, Jaurand MC, Johnson KR, Wheelock MJ, Kleinszanto AJ, Salazar H. The Differential Expression of N-Cadherin and E-Cadherin Distinguishes Pleural Mesotheliomas from Lung Adenocarcinomas. Human Pathology. 1995 Dec;26(12):1363-9.
Loffert D, Schaal S, Ehlich A, Hardy RR, Zou YR, Muller W, Rajewsky K. Early B-Cell Development in the Mouse - Insights from Mutations Introduced by Gene Targeting. Immunological reviews. 1994 Feb;137:135-53.
Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK. Phase-I Trial of Recombinant Macrophage-Colony-Stimulating Factor and Recombinant Gamma-Interferon - Toxicity, Monocytosis, and Clinical Effects. Cancer Research. 1994 Aug;54(15):4084-90.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term antibody

antibody expression monoclonal- protein mice in-vitro immunoglobulin antigen escherichia-coli segments transgenic mice viral-infection clonal selection utilization light-chain tyrosine kinase inhibitor beta-catenin BEVACIZUMAB overexpression Pd-l1 lymphocytes-b fragments autoimmune-disease bcl-2 proliferation ectromelia-virus clinical III TRIAL lambda-genes h-chain cytotoxicity efficacy membrane glycoprotein treatment strategies normal mouse marrow rearrangement renal cell carcinoma BREAST-CANCER malignant mesothelioma B cell receptor cetuximab signal transduction penetration ABC transporter receptor phase 2 TARGETING PROPERTIES gene-expression dna integration immunoglobulin sequences PHARMACOKINETIC MODEL posttransfusion hepatitis cell-adhesion molecule positron emission tomography HUMAN MONOCLONAL-ANTIBODY epithelial mesothelioma breast-cancer CD6 human type-2 ramucirumab IN-VIVO affinity gene product(s) mousepox protein-kinase-c cyto-toxicity repertoire bone- protection phosphatidylinositol 3-kinase apoptosis probabilistic model responses gene immunotherapy fusion cytotoxic T lymphocytes CD4(+) T lymphocytes-viral immunology-viral pathogenesis SUBCUTANEOUS TUMORS properties e-cadherin autoantibodies monoclonal preclinical transcriptase natural host locus region gene-expression single chain Fv lineage SELECTION NUDE-MICE Oncology isotypic exclusion allelic exclusion chronic lymphocytic-leukemia follicular c-erbB-2 metastatic polymerase chain-reaction ImmunoPET CANCER TUMORS mouse lymphocytes-t GROWTH NETWORK chromosomal organization CD19 d-mu protein mouse HYPERTENSION immune- lymphocytes binding- ACUTE MYELOID-LEUKEMIA response SUNITINIB site-specific n-cadherin CELL LUNG-CANCER blood-donors reverse- c virus lymphoma PHASE-III TRIAL tyrosine kinase TYROSINE KINASE INHIBITORS fc-receptors HER-2 affibody-imaging-SKOV-3-tumour antisense oligonucleotides complementary B lymphocyte L STOP c-kit pulmonary adenocarcinoma METASTATIC COLORECTAL-CANCER lung adenocarcinoma SORAFENIB phage display libraries viral replication PROTEIN-INTERACTION preintegration complex monoclonal-antibodies erlotinib plakoglobin resistance CD5 transcript mediated resistance phage antibody libraries
Last updated on Friday, January 03, 2020